The validity of shortened multiple-breath washout testing using sulfur hexafluoride in the assessment of patients with COPD.
Autor: | Daynes E; Centre of Exercise and Rehabilitation Sciences, NIHR Leicester Biomedical Research Centre - Respiratory, Leicester, UK., Greening N; Centre of Exercise and Rehabilitation Sciences, NIHR Leicester Biomedical Research Centre - Respiratory, Leicester, UK., Owers-Bradley J; School of Physics and Astronomy, University of Nottingham, Nottingham, UK., Singh SJ; Centre of Exercise and Rehabilitation Sciences, NIHR Leicester Biomedical Research Centre - Respiratory, Leicester, UK., Siddiqui S; NIHR Leicester Biomedical Research Centre - Respiratory, Leicester, UK. |
---|---|
Jazyk: | angličtina |
Zdroj: | ERJ open research [ERJ Open Res] 2021 Aug 02; Vol. 7 (3). Date of Electronic Publication: 2021 Aug 02 (Print Publication: 2021). |
DOI: | 10.1183/23120541.00379-2020 |
Abstrakt: | Introduction: COPD affects the small airways and is associated with ventilation heterogeneity. There are little data on the multiple-breath washout (MBW) in patients with COPD, particularly the variability over 8 weeks, using a shortened sulfur hexafluoride (SF Methods: The MBW was performed on patients with COPD to determine ventilation heterogeneity globally (LCI), at conductive (S Results: Eighty-four subjects were recruited to perform LCI and spirometry with 20 subjects performing the repeatability protocol. There were weak correlations between forced expiratory volume in 1 s ( FEV Conclusions: The LCI is repeatable within and between visits. There are weak correlations with measures of spirometry. A shortened LCI Competing Interests: Conflict of interest: E. Daynes reports that Actegy Ltd funds a commercial trial from which the present data were obtained. Conflict of interest: N. Greening has nothing to disclose. Conflict of interest: J. Owers-Bradley has nothing to disclose. Conflict of interest: S. Singh reports that Actegy Ltd funds a commercial trial from which the present data were obtained. Conflict of interest: S. Siddiqui reports advisory boards for and speaker fees from AstraZeneca, GSK, Novartis, Roche, Boehringer Ingelheim, Owlstone Medical, Mundipharma and ERT Medical, outside the submitted work. (Copyright ©The authors 2021.) |
Databáze: | MEDLINE |
Externí odkaz: |